beta

BCTX

BriaCell Therapeutics Corp

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

briacell therapeutics corp immunotherapy approaches to cancer management briacell is a los angeles headquartered biotechnology company focused on immunotherapy treatments for cancer management. to date, the company has been successful in developing its patented "briavax" vaccine and implementing two compelling fda phase-i studies with late-stage breast cancer patients, demonstrating unique and unprecedented results. briacell is focused on aggressively moving towards launching its next clinical trial, a phase-i/ii study, in order to apply its vaccine to a larger number of breast cancer patients and effectively progress its technology along the value chain. while the current corporate focus is breast cancer, the company has an eye towards potentially applying its vaccine technology to certain other cancer types as well.

Market Cap: 49.9 Million

Primary Exchange: NASDAQ

Website: briacell.com

Shares Outstanding: 16 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 1.105911984417338

Sector: Manufacturing

Industry: Pharmaceutical Preparation Manufacturing

Ethical Flags

Longest drawdown: 600 trading days

From: 2022-04-08 To: 2024-03-07

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud